DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

Information source: Abbott
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV-1 Infections

Intervention: Lopinavir/ritonavir (Kaletra) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Abbott

Official(s) and/or principal investigator(s):
Jian LI, MD, Study Chair, Affiliation: Abbott (China)

Summary

This post-marketing observational study is conducted for obtaining data on clinical, biological and virological outcomes, compliance and tolerability of using a

lopinavir/ritonavir (LPV/r) - containing regimen for the treatment of naïve or experienced

patients infected with human immunodeficiency virus type 1 (HIV-1) in China. Although LPV/r is frequently used world-wide, the evaluation of the outcomes, compliance, and tolerance of anti-HIV strategies in real life is still a major challenge in the management of HIV-infected patients who are on a life-long therapy, especially in China. This study will help to develop effectiveness and safety profile of the lopinavir/ritonavir containing regimen in Chinese HIV-1 infected patients, provide more choices of anti-HIV-1 strategies to Chinese experts and benefits Chinese HIV-1 infected patients.

Clinical Details

Official title: Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China: A Multicenter Post-Marketing Observational Study

Study design: Time Perspective: Prospective

Primary outcome:

Evolution of the HIV Viral Response

Evolution of CD4 Count

Evolution of the Tolerance Issues

Secondary outcome:

Number of Participants Who Missed Doses, Interrupt or Discontinue Regimen, and Experience Changes in Dosage or of Combination Regimen

Adverse Events Observed and Development of Lipodystrophy Lesion and Their Locations

The Duration on Treatment Until Development of an Adverse Event Leading to Treatment Discontinuation or Until Escape From Treatment

Detailed description: It is planned to enroll approximately 100 patients in total. This will be a multicenter post-marketing observational study in China mainland.

Each patient will be observed during his/her lopinavir/ritonavir - containing treatment

regimen for a maximum period of 18 months. If the physician decides to permanently discontinue lopinavir/ritonavir before the end of the planned observational period of 18 months, the reason for the discontinuation and the new treatment regimen prescribed will be documented. The next routine follow-up visit will be the termination visit for this patient in this study. This post-marketing observational study will be conducted in a prospective, single-arm, multicenter format. As this study is observational in nature, its follow-up is not interventional and is left to the judgment of each physician within the 18-month period, which defines the survey for each patient. For indicative purpose, follow-up of patients should enable approximately 4 patient visits during this period. These visits will take place at average intervals of 6 months, apart from the first visit following inclusion (usually at the end of the first 3 treatment months) and apart from visits required because of an intercurrent event. If treatment with lopinavir/ritonavir is discontinued, standard practice is to review the patient after a period of 3 months. For these reasons, the most likely visits are defined as "V1", "V2", "V3", "V4" although numbers and dates will depend only on the decision of the physician. As a result, failure to meet these suggested dates will not constitute a deviation of the protocol.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients infected by HIV-1 who are over 18 years old

- Patients who belong to one of the following cohorts:

- Antiretroviral naïve patients

- Antiretroviral experienced patients, irrespective to their immune and viral

status and current antiretroviral therapy Exclusion Criteria:

- Patients who have been treated with lopinavir/ritonavir

- Patients who are being treated or will be treated with drugs at risk of interactions

with lopinavir/ritonavir

- Patients who are not tolerant to lopinavir/ritonavir

- Patients who have uncontrolled AIDS defining disease

- Patients participating in another clinical trial

Locations and Contacts

Site Reference ID/Investigator# 7244, Guangdong 510060, China

Site Reference ID/Investigator# 27865, Kunming 650118, China

Site Reference ID/Investigator# 27864, Shanghai 201508, China

Site Reference ID/Investigator# 27863, Shenzhen 518020, China

Site Reference ID/Investigator# 27866, Zhengzhou 450061, China

Additional Information

Starting date: April 2008
Last updated: July 7, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017